Gastroenterology

Latest News

colorectal cancer | Image credit: Dr_Microbe - stock.adobe.com
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

February 8th 2025

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.

syringe biosimilar | Image credit: Luluraschi - stock.adobe.com
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars

February 5th 2025

Wezlana | background image: autoinjector pen | Image credit: nazif - stock.adobe.com
Welcome Wezlana: The First Stelara Biosimilar to Launch in the US

January 31st 2025

eye on pharma banner
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets

January 26th 2025

IBD | Image credit: Jo Panuwat D - stock.adobe.com
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar

January 25th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.